undamentalytics Newsletter
Sign in

Universe Pharmaceuticals Inc (UPC) stock

Add to watchlist

Add holding +

NASDAQ: UPC Nasdaq Pharmaceuticals

D Fundamentals grade

Universe Pharmaceuticals Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Universe Pharmaceuticals Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds4 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Universe Pharmaceuticals files

Where Universe Pharmaceuticals stands after its latest Filing

Revenue for the twelve months was $17.9bn, down 22.4% on a year earlier, a smaller fall than the 28.7% decline a quarter earlier. That puts it 66 of 74 for growth among the pharmaceuticals companies we cover. Free-cash-flow margin fell to -29.8% from -5.2% a year earlier. Operating margin narrowed to -16.3% from 28.3%. The diluted share count is down 96.7% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 3 financial-health checks.

Our model value for Universe Pharmaceuticals is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Universe Pharmaceuticals Inc's trailing-twelve-month revenue fell 22.4% year on year, with a free-cash-flow margin of -29.8%. Where it stands out: change in share count of -96.7% ranks 1 of 62 pharmaceuticals companies we cover. Where it lags: days sales outstanding of 266 days ranks 57 of 59 pharmaceuticals companies we cover.

Current signal Share count shrinking (buybacks): Diluted shares outstanding fell 96.7% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 18.5 points on a year ago.
  • Shrinking share count. Diluted shares fell 96.7% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $33.6bn.

Things to watch

  • Revenue shrinking. Revenue fell 22.4% over the last 12 months.
  • Loss-making. Operating margin is -16.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -29.8% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 352% and a beta of 4.3 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 266 days ranks 57 of 59 pharmaceuticals companies we cover (median 72 days).

Price chart

  • 1 day-1.3%
  • 1 week-49.0%
  • 1 month-67.3%
  • This year-61.4%
  • 1 year-68.9%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$17.9B
Operating margin
-16.3%
Net margin
-20.6%
EPS (TTM, diluted)
$-8055.03

Growth

Revenue growth
−22.4%
Change in growth rate
+6.3 pts
Share count change
−96.7%

Cash

Free cash flow (TTM)
-$5.3B
FCF margin
-29.8%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for UPC from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Universe Pharmaceuticals Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Universe Pharmaceuticals Inc as an operating company, with every model that fits that kind of business. Cost of equity 10.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.26 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$71000 ~$71000–$81000 Left out: out of range vs price (48564.90x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$3500 Left out: out of range vs price (2398.29x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$17000 ~$33000–$140000 Left out: out of range vs price (11708.61x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Universe Pharmaceuticals Inc with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$8892.00$2034.00$570.00$146.40$4.20
Market value$28.1bn$12m$3.4bn$2.0bn$2m
+ Net debt (− = net cash)−$4m−$5.7bn−$5.3bn−$23.6bn−$24.3bn
Enterprise value$28.1bn−$5.7bn−$1.8bn−$21.6bn−$24.3bn
Multiples
Price / sales n/m0.3x0.1x0.1x0.0x
Price / earnings n/m————
Price / free cash flow ——3.2x——
EV / EBITDA n/m————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Universe Pharmaceuticals Inc: too few analysts cover it.

Positioning

Short interest
0.6%
of tradable shares
Days to cover
0.72
at average volume
Short interest, 1 month
−60%
to October 15, 2026
Held by institutions
2%
of shares
Held by insiders
88.8%
of shares
Employees
216
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 20222023202420252026 to date
Return
UPC−11%−77%−98%−84%−61%
Industry peers (median)−52%−13%−2%+9%−12%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
UPC42%25%50%33%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
UPC−72%−92%−99%−89%−88%
S&P 500−25%−10%−8%−19%−9%

Worst fall since March 23, 2021: 100% from April 5, 2021 to November 2, 2026. Getting back needed a 1383574% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.47 – $12.18
From 52-week high
−87.9%
vs 50-day average
−64.5%
vs 200-day average
−61.3%
Volatility (1 year)
352%
Beta vs S&P 500
4.28

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Universe Pharmaceuticals Inc in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Universe Pharmaceuticals Inc
$0 $10B $20B $30B $40B FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY19 Q4: $33.2M Revenue (TTM), FY20 Q4: $30.7M Revenue (TTM), FY21 Q4: $48M Revenue (TTM), FY22 Q4: $40.1M Revenue (TTM), FY23 Q4: $32.3B Revenue (TTM), FY24 Q4: $23B Revenue (TTM), FY25 Q4: $17.9B $17.9B

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY19 Q4 $33.2M
FY20 Q4 $30.7M
FY21 Q4 $48M
FY22 Q4 $40.1M
FY23 Q4 $32.3B
FY24 Q4 $23B
FY25 Q4 $17.9B
Revenue growth, TTM YoY Universe Pharmaceuticals Inc
-50000% 0% 50000% 100000% FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY20 Q4: -7.6% Revenue growth, TTM YoY, FY21 Q4: 56.3% Revenue growth, TTM YoY, FY22 Q4: -16.3% Revenue growth, TTM YoY, FY23 Q4: 80383.8% Revenue growth, TTM YoY, FY24 Q4: -28.7% Revenue growth, TTM YoY, FY25 Q4: -22.4% -22.4%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY20 Q4 -7.6%
FY21 Q4 56.3%
FY22 Q4 -16.3%
FY23 Q4 80383.8%
FY24 Q4 -28.7%
FY25 Q4 -22.4%
Operating margin (TTM) Universe Pharmaceuticals Inc
-40% -20% 0% 20% 40% FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY19 Q4: 29.4% Operating margin (TTM), FY20 Q4: 33.4% Operating margin (TTM), FY21 Q4: 28.3% Operating margin (TTM), FY22 Q4: -17.5% Operating margin (TTM), FY23 Q4: -12.3% Operating margin (TTM), FY24 Q4: -34.8% Operating margin (TTM), FY25 Q4: -16.3% -16.3%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY19 Q4 29.4%
FY20 Q4 33.4%
FY21 Q4 28.3%
FY22 Q4 -17.5%
FY23 Q4 -12.3%
FY24 Q4 -34.8%
FY25 Q4 -16.3%
FCF margin (TTM) Universe Pharmaceuticals Inc
-50% 0% 50% FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY19 Q4: 39.5% FCF margin (TTM), FY20 Q4: 19.7% FCF margin (TTM), FY21 Q4: -5.2% FCF margin (TTM), FY22 Q4: -3.5% FCF margin (TTM), FY23 Q4: 3.3% FCF margin (TTM), FY24 Q4: -42.2% FCF margin (TTM), FY25 Q4: -29.8% -29.8%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY19 Q4 39.5%
FY20 Q4 19.7%
FY21 Q4 -5.2%
FY22 Q4 -3.5%
FY23 Q4 3.3%
FY24 Q4 -42.2%
FY25 Q4 -29.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025
Income
Revenue 0.0 0.0 0.0 0.0 32.3 23.0 17.9
Gross profit 0.0 0.0 0.0 0.0 10.3 6.1 6.3
EBITDA 0.0 0.0 0.0 −0.0 −3.5 −7.5 −2.4
Operating income 0.0 0.0 0.0 −0.0 −4.0 −8.0 −2.9
Net income 0.0 0.0 0.0 −0.0 −6.6 −8.7 −3.7
Diluted EPS $2.82 $2.82 $3.58 −$1309.11 −$1089.21 −$626.96 −$8.06
Growth (year on year)
Revenue — −7.6% +56.3% −16.3% +>999% −28.7% −22.4%
EBITDA — +4.8% +31.7% −146.2% — — —
Operating income — +5.1% +32.6% −151.7% — — —
Net income — +0.1% +49.8% −169.9% — — —
Diluted EPS — 0.0% +27.0% <−999% — — —
Margins
Gross margin 40.3% 45.9% 52.8% 54.5% 31.9% 26.4% 35.3%
EBITDA margin 30.6% 34.7% 29.3% −16.2% −10.7% −32.7% −13.4%
Operating margin 29.4% 33.4% 28.3% −17.5% −12.3% −34.8% −16.3%
Net margin 22.7% 24.6% 23.6% −19.7% −20.4% −37.9% −20.6%
Free-cash-flow margin 39.5% 19.7% −5.2% −3.5% 3.3% −42.2% −29.8%
Cash flow
Cash from operations 0.0 0.0 −0.0 −0.0 1.1 −9.5 −5.1
Capital spending 0.0 0.0 0.0 0.0 0.0 0.2 0.3
Free cash flow 0.0 0.0 −0.0 −0.0 1.1 −9.7 −5.3
Balance sheet
Cash 0.0 0.0 0.0 5.7 5.3 29.5 33.6
Total debt 0.0 0.0 0.0 0.0 0.0 5.9 9.3
Net debt (negative = net cash) −0.0 −0.0 −0.0 −5.7 −5.3 −23.6 −24.3
Diluted shares 3m 3m 3m — 6m 14m —
Returned to shareholders
Dividends 0.0 — — — — — —
Total returned 0.0 — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · September 30, 2025
What it owns · $69.3bn
Short-term assets $53.6bnLonger-term assets $15.7bn
What it owes, and who funded it · $69.3bn
Short-term liabilities $13.2bnLonger-term liabilities $0mShareholders' equity $56.1bn
  • Short-term assets cover short-term liabilities $53.6bn of assets due within a year against $13.2bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $53.6bn short-term assets against $0 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$2.9bn against $289m of interest.

From Universe Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
−96.7%
year over year
R&D spending
3.8%
of revenue
Days sales outstanding
266 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated UPC VTRS HLN BHC ZTS GSK Median
Revenue, last 12 months $17.9bn $14.7bn $14.6bn $11.1bn $9.5bn $43.1bn $276m
Revenue growth, last 12 months −22.4% 4.4% 1.3% 10.8% 1.5% 7.5% 9.9%
Revenue growth, 3-year average — −1.9% — 9.2% 5.0% — 5.5%
Revenue growth, latest quarter — 4.9% — 9.7% −0.2% — 6.5%
Gross margin 35.3% 34.8% 64.2% — 71.5% 72.4% 62.0%
Operating margin −16.3% −0.6% 21.9% 11.2% — 24.3% −5.9%
Operating margin, 3-year average — −6.4% — 14.8% — 18.5% −7.4%
Net margin −20.6% −2.8% 15.1% −7.6% 27.5% 17.5% −7.3%
Cash from operations / revenue −28.3% 15.8% 23.9% 19.9% 29.8% 23.7% 10.2%
Free-cash-flow margin −29.8% 13.3% 21.0% 16.8% 24.3% 19.6% 8.6%
Free-cash-flow margin, 3-year average — 13.0% — 13.0% 24.0% 21.9% 7.4%
Stock pay / revenue — 1.2% 0.8% 2.2% 1.0% 1.1% 3.6%
Change in share count −96.7% −0.5% −1.6% 1.9% −4.2% −0.6% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -22.4% 10.0% 66 of 74
Change in growth rate Growth +6.3pp -0.3pp 10 of 74
Gross margin Profitability 35.3% 59.8% 44 of 59
Operating margin Profitability -16.3% -5.9% 40 of 67
Net margin Profitability -20.6% -7.3% 50 of 75
Free-cash-flow margin Cash generation -29.8% 10.1% 60 of 74
Change in share count Balance sheet -96.7% 1.5% 1 of 62
Days sales outstanding Balance sheet 266 days 72 days 57 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$228,361
Institutions reporting
4
Positions opened / closed
4 / 0

Top buyers and sellers, Q2 2026: 4 institutions bought and 0 sold ; the biggest buyer was HRT Financial LP (+17K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $103,000 17K 45.1% —
UBS Group AG $87,639 14K 38.4% —
Osaic Holdings, Inc. $37,649 6K 16.5% —
Caitong International Asset Management Co., Ltd $73 0K 0.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Universe Pharmaceuticals Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Data status

When each part of this page on Universe Pharmaceuticals Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Universe Pharmaceuticals Inc in brief

What does Universe Pharmaceuticals Inc do?
Universe Pharmaceuticals Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in September.
What is Universe Pharmaceuticals Inc's stock ticker?
Universe Pharmaceuticals Inc trades under the ticker UPC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Universe Pharmaceuticals Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Universe Pharmaceuticals Inc reported revenue of $17.9B, 22.4% lower than a year earlier, according to its SEC filings.
What is Universe Pharmaceuticals Inc's free cash flow?
Universe Pharmaceuticals Inc's free-cash-flow margin is -29.8% of revenue over the trailing twelve months, ranking 60 of the 74 pharmaceuticals companies we cover.
Who are Universe Pharmaceuticals Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, UBS Group AG and Osaic Holdings, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Universe Pharmaceuticals Inc's market cap?
On September 30, 2025, Universe Pharmaceuticals Inc's market capitalisation was about $1.9M and net debt of -$24.3B. Market figures come from third-party market data and may be delayed.
Who are Universe Pharmaceuticals Inc's competitors?
In our Pharmaceuticals peer group, the companies closest to Universe Pharmaceuticals Inc are Viatris, Haleon plc, Bausch Health Companies Inc., Zoetis and GSK plc. The side-by-side comparison below sets their revenue, margins and growth against Universe Pharmaceuticals Inc's.